

**Ordering Information**  
 Web [www.encorbio.com](http://www.encorbio.com)  
 Email [admin@encorbio.com](mailto:admin@encorbio.com)  
 Phone 352-372-7022  
 Fax 352-372-7066


**HGNC Name:** APP  
**UniProt:** P05067  
**RRID:** AB\_2572226  
**Immunogen:** 1-42 human amyloid A $\beta$  epitope is sequence 1-16  
**Format:** Purified antibody at 1mg/mL in 50% PBS, 50% glycerol plus 5mM NaN<sub>3</sub>  
**Storage:** Stable at 4°C for one year, for longer term store at -20°C  
**Recommended dilutions:**  
 WB: 1:1,000-1:2,000. IF/ICC: 1:1,000. IHC: 1:2,000.

#### References:


- Levites Y, et al. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. *J. Clin. Invest* 116:193-201 (2006).
- Wang A, et al. Robust Amyloid Clearance in a Mouse Model of Alzheimer's Disease Provides Novel Insights into the Mechanism of Amyloid- $\beta$  Immunotherapy. *J. Neuroscience*, March 16, 2011 • 31:4124-36 (2011).
- Kim J, et al. A $\beta$ 40 Inhibits Amyloid Deposition In Vivo. *J. Neurosci.* 27:627-33 (2007).
- Das P, et al. Amyloid- $\beta$  Immunization Effectively Reduces Amyloid Deposition in FcR $\gamma$ -/- Knock-Out Mice. *J. Neurosci.* 23:8532-8 (2003).
- Sagi SA, et al. Substrate Sequence Influences  $\gamma$ -Secretase Modulator Activity: Role of the Transmembrane Domain of The Amyloid Precursor Protein. *J. Biol. Chem.* 286:39794-803 (2011).
- Fernandez-Funez P, et al. Holdase activity of secreted Hsp70 masks amyloid- $\beta$ 42 neurotoxicity in *Drosophila*. 2016.
- Moore BD, et al. Overlapping profiles of A $\beta$  peptides in the Alzheimer's disease and pathological aging brains. *Alz. Res. Therap.* 4:18 (2012).

This antibody has been utilized in numerous other peer-reviewed publications many of which can be found by searching Google Scholar for "AB9 AND Amyloid" or by selecting [here](#).

Applications	Host	Isotype	Molecular Wt.	Species Cross-Reactivity
WB, IF/ICC, IHC	Mouse	IgG2a heavy, $\kappa$ light	~5kDa	Hu



Blot of amyloid- $\beta$  peptide preparation probed with MCA-AB9. The MCA-AB9 antibody recognizes monomeric amyloid- $\beta$  peptide running at ~5kDa and also higher molecular weight amyloid- $\beta$  aggregates.



Immunohistochemical analysis of a region of cerebral cortex from an Alzheimer's disease (AD) patient stained with MCA-AB9, the signal detected with a secondary anti-mouse antibody coupled to HRP, signal revealed with DAB. Senile plaques are labeled "SP". The region of the lowest of the three plaques is shown in the inset stained with the fluorescent dye thioflavin-S. This dye binds to not only the senile plaque but also a neurofibrillary tangle (NFT), the other pathological hallmark of AD, which do not contain A $\beta$ .

#### Background:

**Alzheimer's disease (AD)** is a serious and increasingly common age related dementia which is characterized by the formation of **senile plaques** which are extracellular accumulations of insoluble proteins. Another characteristic of AD is the formation of **neurofibrillary tangles** inside neurons. A major component of the senile plaques is  $\beta$ -amyloid, a.k.a. A $\beta$ , a peptide the predominant forms of which are 42 or 40 amino acids in length. The A $\beta$  peptide is derived by proteolytic cleavage from a much larger protein membrane localized called the **amyloid precursor protein (APP)**. Deposition of A $\beta$  is increased as a result of certain point mutations in the APP gene and by mutations in presenilins and other genes. The presence of certain alleles of the ApoE gene also increase the likelihood of progressing to AD.

The MCA-AB9 is a mouse monoclonal antibody which made against the A $\beta$  peptide and has been described in a peer reviewed publication (1). It was found to bind to the N-terminal peptide of A $\beta$ , and has become very widely used (e.g. 2-6). It works well on western blots and reveals senile plaques in AD brains by ICC and IHC, for further IHC see data under "Additional Info" tab. Much interest has focused on the use of humanized monoclonal antibodies to target and potentially clear A $\beta$  from the brains of Alzheimer patients. This antibody has been used in this manner as a proof of concept in mouse models of AD (e.g. 2,3). This antibody was originally made in the Mayo Clinic in Jacksonville, Florida, in the then laboratory of Dr. Todd Golde.

**FOR RESEARCH USE ONLY. NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE.**

#### Abbreviation Key:

**mAb**—Monoclonal Antibody **pAb**—Polyclonal Antibody **WB**—Western Blot **IF**—Immunofluorescence **ICC**—Immunocytochemistry  
**IHC**—Immunohistochemistry **E**—ELISA **Hu**—Human **Mo**—Monkey **Do**—Dog **Rt**—Rat **Ms**—Mouse **Co**—Cow **Pi**—Pig **Ho**—Horse **Ch**—Chicken  
**Dr**—*D. rerio* **Dm**—*D. melanogaster* **Sm**—*S. mutans* **Ce**—*C. elegans* **Sc**—*S. cerevisiae* **Sa**—*S. aureus* **Ec**—*E. coli*.